Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) Income from Continuing Operations (2023 - 2026)

Alto Neuroscience has reported Income from Continuing Operations over the past 4 years, most recently at 26122000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 26122000.0 for Q1 2026, down 80.81% from a year ago — trailing twelve months through Mar 2026 was 73905000.0 (down 18.42% YoY), and the annual figure for FY2025 was 62230000.0, down 1.79%.
  • Income from Continuing Operations reached 26122000.0 in Q1 2026 per ANRO's latest filing, down from 16069000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7295000.0 in Q1 2023 and bottomed at 26122000.0 in Q1 2026.
  • Median Income from Continuing Operations over the past 4 years was 14447000.0 (2025), compared with a mean of 14332000.0.
  • The largest annual shift saw Income from Continuing Operations crashed 82.47% in 2024 before it rose 15.93% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 11383000.0 in 2023, then tumbled by 33.49% to 15195000.0 in 2024, then decreased by 5.75% to 16069000.0 in 2025, then crashed by 62.56% to 26122000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for ANRO at 26122000.0 in Q1 2026, 16069000.0 in Q4 2025, and 14069000.0 in Q3 2025.